Flatley

[redacted] Taps Adam Flatley to Lead [rTIC Ghost Group

Retrieved on: 
Thursday, January 19, 2023
Data Management, Security, Apps, Applications, Technology, Software, Internet, Intelligence, Ghost Group, Sourcefire Vulnerability Research Team, Government, Risk, U.S. Department of Defense Strategy for Operating in Cyberspace, Flatley, Organization, Director of Operations, Research, Security agency, Noise, Financial services, Weapon, Risk management, Redact

Redacted , the mission-driven cybersecurity company that levels the playing field against attackers, today announced that Adam Flatley has been promoted to Vice President of Intelligence leading the Redacted Intelligence Cell, recently renamed [rTIC Ghost Group.

Key Points: 
  • Redacted , the mission-driven cybersecurity company that levels the playing field against attackers, today announced that Adam Flatley has been promoted to Vice President of Intelligence leading the Redacted Intelligence Cell, recently renamed [rTIC Ghost Group.
  • The team of battle-hardened cybersecurity and intelligence experts focuses on technical and human intelligence collection, analysis, and production.
  • [rTIC Ghost Group’s efforts generate the highest caliber, actionable intelligence that underpins all Redacted products and services.
  • “Every organization has its own unique threat landscape that requires an equally unique strategy for defense,” said Flatley.

Zymergen Debuts Automation Business and Shares Program Portfolio at 40th Annual JP Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 11, 2022
Forward-looking statement, Research, Technology, SAN, Biology, Private Securities Litigation Reform Act, SEC, Enzyme, Polymer, Growth, Flatley, Solution, GLOBE, Cellulose, Automation, History, Electronics, Time, Industry, Efficiency, Vaccinia, Data collection, VCE, Family, RNA transfection, Organization, Partnership, Fine chemical, 3D printing, Risk management

Zymergens Automation business delivers proven automation technology to organizations interested in improving the throughput, efficiency, and reliability of their lab operations.

Key Points: 
  • Zymergens Automation business delivers proven automation technology to organizations interested in improving the throughput, efficiency, and reliability of their lab operations.
  • Automation technology has advanced slowly over the last decade, resulting in largely under-automated labs, limiting scientific progress, growth, and scalability.
  • Our Automation solutions have been developed in tight iteration with our lab scientists, data scientists and software engineers in a way that traditional vendors can seldom access.
  • Our Automation business can help organizations lower the barrier to entry by providing scalable and fully supported automation solutions.

OST Reports: Hospitals move to the cloud at record pace

Retrieved on: 
Thursday, October 21, 2021
Cloud, CIO, OST, Efficiency, Health, Maintenance, Architecture, Budget, Multimedia, Flatley, Health insurance

Epic infrastructure requirements continue to grow by 20 to 40 percent each year, and often outgrow planned infrastructure lifecycles.

Key Points: 
  • Epic infrastructure requirements continue to grow by 20 to 40 percent each year, and often outgrow planned infrastructure lifecycles.
  • Leveraging Cloud services for Epic infrastructure offers cost-savings, faster deployments and simplified infrastructure management.
  • "One of the primary benefits of moving Epic to the cloud is cost savings," Nienhuis said.
  • Learn how and discover OST's phased methodology for implementing Epic workloadsin the cloud at our upcoming webinar.

Industry Pioneer Jay Flatley Named as Chairman of Zymergen Board of Directors

Retrieved on: 
Wednesday, April 14, 2021
Articles, DNA sequencing, Illumina, Inc., Microarrays, Flatley, Board of directors, Business, Biology

b'EMERYVILLE, Calif., April 13, 2021 /PRNewswire/ -- Leading biofacturing company Zymergen has named Jay Flatley as the Chairman of the Board of Directors, effective immediately.

Key Points: 
  • b'EMERYVILLE, Calif., April 13, 2021 /PRNewswire/ -- Leading biofacturing company Zymergen has named Jay Flatley as the Chairman of the Board of Directors, effective immediately.
  • With that backdrop, I am delighted to announce that Jay Flatley has been appointed to serve as Chairman of Zymergen\'s Board of Directors.
  • "\n"I am excited about the future of Zymergen and the ability of their biofacturing platform to revolutionize materials science," said Mr. Flatley.
  • "\nBeyond his role as Chairman of Zymergen\'s Board, Mr. Flatley will continue as Chairman of the Board of Directors at Illumina through May 26, 2021, where he previously served as CEO from 1999 until 2016.

Illumina Announces Board Changes

Retrieved on: 
Thursday, March 18, 2021
Health, Infectious diseases, Genetics, Research, Science, Biotechnology, DNA sequencing, Illumina, Inc., Microarrays, John W. Thompson, Flatley, Illumina, Lluís Companys, Businesspeople, Biology, Biotechnology

Illumina, Inc. (NASDAQ: ILMN) (the Company) today announced that Jay Flatley has decided to step down from the Board of Directors and John W. Thompson will be appointed as the Companys new Chair of the Board.

Key Points: 
  • Illumina, Inc. (NASDAQ: ILMN) (the Company) today announced that Jay Flatley has decided to step down from the Board of Directors and John W. Thompson will be appointed as the Companys new Chair of the Board.
  • Illumina has significant opportunities ahead and I am confident that John, Francis and the entire Illumina leadership team will continue the Companys strong legacy of innovation and execution for long-term success.
  • Mr. Flatley led Illumina as CEO from 1999 until mid-2016, served as Executive Chair from mid-2016 through 2019, and currently serves as Chair of the Board.
  • Mr. Thompson is a member of the board of trustees for the Wetlands America Trust and was formerly a member of the national board of Teach for America.